Johnson & Johnson’s 14.9 million recipients are a step closer to getting booster shots, after feeling ignored by public-health agencies for months.
…
Johnson & Johnson’s 14.9 million recipients are a step closer to getting booster shots, after feeling ignored by public-health agencies for months. On Tuesday, J&J said it had submitted data to the Food and Drug Administration and asked the agency to authorize booster shots for emergency use. It will be up to the Centers for Disease Control and Prevention and FDA to evaluate that request, green-light the shots, and determine who should get the boosters. An FDA advisory committee will meet later next week to discuss both J&J and Moderna’s booster shot applications. Prior to Tuesday’s announcement, J&Jers described feeling remorse about their one-shot status. « I count myself among those few and now not-so-proud, » New York Magazine’s Benjamin Hart wrote last month, in a piece with the simple headline: « Johnson & Johnson & Regret. » The shot, a convenient one-and-done single dose, suffered a kind of fall from grace during its rollout: A factory mix-up led vaccine ingredients to be improperly mixed, then the CDC issued a pause on the vaccine altogether while they examined the risk of an extremely rare blood clot condition. Regulators later added a warning label for women under 50.
